Commentary

Video

Dr Krishnan on the Role of Cilta-Cel in High-Risk Multiple Myeloma

Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.

Amrita Krishnan, MD, executive medical director, Hematology, City of Hope Orange County; director, the Judy and Bernard Briskin Multiple Myeloma Center; professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the potential role for CAR T-cell therapies, such as ciltacabtagene autoleucel (Carvykti; cilta-cel), in the early-relapsed setting for patients with high-risk multiple myeloma.

The phase 3 CARTITUDE-4 trial (NCT04181827) compared the BCMA-directed CAR T-cell therapy, cilta-cel with standard-of-care (SOC) regimens in a population of functionally high-risk patients with relapsed/refractory multiple myeloma. Findings from this trial supported the April 2024 FDA approval of cilta-cel for adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

At the 2024 ASCO Annual Meeting, long-term follow-up data from the high-risk population in CARTITUDE-4 highlighted the potential of cilta-cel in the early relapsed setting, Krishnan begins. The results showed a significant improvement in median progression-free survival (PFS) and overall response rate (ORR) with cilta-cel vs SOC regimens, she reports. Within the high-risk subset, the median PFS with cilta-cel was comparable with that of standard-risk patients, suggesting that cilta-cel could mitigate the impact of high-risk features in early relapse.

However, the decision to use cilta-cel in the early-relapsed setting remains highly individualized, and involves balancing the risks and benefits for each patient, Krishnan states. Cilta-cel may be the preferred approach for some patients who have been CD38-exposed, but not refractory. There are also other groups of patients for whom that may not be the case, she cautions. The choice between cilta-cel and other therapies accordingly depends on several factors, including disease characteristics, patient comorbidities, and shared decision-making between the patient and healthcare provider, Krishnan emphasizes. Although relatively low, the risk of developing neurologic toxicities or secondary malignancies are critical considerations in the shared decision-making process, she adds. Thus, while cilta-cel has demonstrated substantial benefits in a specific patient subset, its role in the in the early relapsed setting continues to evolve based on emerging data and clinical experience, Krishnan concludes.

Related Videos
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD
Sunil Adige, MD
Nitin Jain, MD
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD